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Abstract
Background: Women with a personal history of breast cancer have a high risk of developing an ipsi- or
contralateral recurrence. We aimed to compare the growth rate of primary breast cancer and recurrences in
women who had undergone prior breast magnetic resonance imaging (MRI).
Methods: Three hundred and sixty-two women were diagnosed with breast cancer and had undergone breast
MRI at the time of diagnosis in our institution (2005 - 2009). Among them, 37 had at least one prior breast MRI
with the lesion being visible but not diagnosed as cancer. A linear regression of tumour volume measured on MRI
scans and time data was performed using a generalized logistic model to calculate growth rates. The primary
objective was to compare the tumour growth rate of patients with either primary breast cancer (no history of
breast cancer) or ipsi- or contralateral recurrences of breast cancer.
Results: Twenty women had no history of breast cancer and 17 patients were diagnosed as recurrences (7 and 10
were ipsi- and contralateral, respectively). The tumour growth rate was higher in contralateral recurrences than in
ipsilateral recurrences (growth rate [10
-3 days
-1] 3.56 vs 1.38, p < .001) or primary cancer (3.56 vs 2.09, p = 0.01).
Differences in tumour growth were not significant for other patient-, tumour- or treatment-related characteristics.
Conclusions: These findings suggest that contralateral breast cancer presents accelerated growth compared to
ipsilateral recurrences or primary breast events.
Background
Better knowledge of breast cancer growth rates has
many implications for diagnosis, treatment and follow-
up. Recent preclinical studies suggest that cancer treat-
ments such as radiotherapy, chemotherapy, and surgery
can induce accelerated repopulation and more aggres-
sive disease arising from surviving tumour cells [1-3].
Among aggressiveness characteristics, the tumour
growth rate is important but seldom available as breast
cancers are not followed-up without treatment. A few
observational studies have retrospectively analyzed
missed cancers on mammograms to evaluate breast can-
cer growth rates. However, mammography is neither the
most sensitive nor the most reliable imaging modality
for detecting or measuring breast cancer.
Breast magnetic resonance imaging (MRI) has been
shown to be more accurate than ultrasound and mam-
mography in estimating the local extent of breast cancer
and assessment of tumour size [4,5]. Moreover, as MRI
is more sensitive than mammography and ultrasound
for breast cancer diagnosis, it is used for screening
women at high risk of breast cancer, follow-up of breast
cancer survivors, and other situations, including “pro-
blem-solving” when standard clinical and imaging eva-
luation do not provide a clear diagnosis [6-9].
Nevertheless, high specificity is lacking, and some can-
cers, although visible as enhancing lesions, are not initi-
ally diagnosed and undergo several follow-up MRI
examinations, thus enabling tumour growth assessment
[10].
In this context of breast cancers that may have under-
gone serial MRI examinations before diagnosis, we
hypothesized that if previously treated primary breast
cancer can promote aggressive recurrences in the clini-
cal setting, then we could observe an increased growth
rate of such recurrences. We conducted a retrospective
study and assessed growth rates of 20 primary breast
cancers, 10 ipsilateral recurrence and 7 contralateral
recurrences of breast cancers in all women that were
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breast MRI scans with a visible lesion prior to diagnosis.
Methods
Approval for this retrospective study was obtained from
our institutional review board, which waived the
requirement for informed consent. This study was com-
pliant with the Health Insurance Portability and
Accountability Act. The study is reported according to
the STROBE statement.
Participants
This retrospective study examined original histological
reports of 362 consecutive patients with breast cancer
diagnosed by biopsy in our institution and with breast
MRI performed at time of diagnosis, between 1 January
2005 and 31 December 2009. 46 patients had undergone
at least one other breast MRI scan prior to diagnosis.
Three patients with cancer not visible on previous MRI
scans (no enhancing lesion) were excluded, along with 6
patients with regional non-mass like enhancement
(lesion volume not measurable with reliability). After
exclusions, there were 37 cases for analysis - 7 women
with ipsilateral breast cancer recurrence, 10 women with
contralateral breast cancer recurrence and 20 women
with primary breast cancer (Figure 1).
Multiple MRI examinations may have been performed
prior to cancer diagnosis because: (a) in 24 cases the
lesion was considered as BIRADS 3 with systematic fol-
low-up planned; (b) in 7 cases the patient underwent
MRI-guided or US-guided biopsy with a non-malignant
result, the lesion was thus monitored by MRI; or (c) in
6 cases there was failure to initially detect a small breast
lesion due to diffuse breast enhancement.
Documented information included patient age at diag-
nosis, patient history of breast cancer and treatment of
primary cancer, menopausal status, breast tumour size,
type, grade, mitotic count.
MRI technique and image analysis
All participants underwent dynamic, contrast-enhanced
breast MRI. Minimum standard criteria were required
for each MRI study performed: a 1.5-T magnet, a dedi-
cated breast-surface coil, and one image obtained before
and dynamic images obtained after the administration of
contrast material, with three-dimensional, T1-weighted,
gradient-echo sequences. Spatial-resolution criteria
included voxels smaller than 0.7 mm in the frequency-
encoding direction, smaller than 1 mm in the phase-
encoding direction, and 3 mm or smaller in the slice
direction, thus providing full coverage of the breast.
Two readers, who were blinded to the pathological
tumour size, independently reviewed the randomized
breast MRI. To avoid confusion with other breast
lesions, the readers were made aware of the location of
the lesions of interest. For each lesion, the greatest axial
diameters, greatest perpendicular diameters, and number
of sections were measured and recorded.
Growth model
The tumour volume was estimated using the formula
for obloid spheroids
V =
4
3
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1
2
a ·
1
2
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1
2
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with a, b, c denoting the mean of the two readers’ dia-
meters measurements.
Several studies showed that decelerating equations
provided better fits for the growth of human breast can-
cer tumours than the exponential law. Such growth
curves can be described by a logistic function or a Gom-
pertz function [11-14]. Both Spratt and Weedon-Fekjaer
used a variant of the log-normal logistic growth model
with a maximum tumour volume of 40 cell doublings,
equalling a ball of 128 mm in diameter, after testing sev-
eral models on a clinical dataset that mostly consisted of
overlooked tumours at earlier mammograms. In the pre-
sent study, we used the same variant of the general
logistic growth model which implies almost exponen-
tional growth for the smallest tumours with growth
decelerating as the tumours approach their supposed
maximum volume [11,12,15].
Mathematically, this equation gives the following speci-
fication of tumour volume, V(t), as a function of time, t:
V(t)=
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where b is the growth rate, Vmax is the maximum
tumour volume (set for a tumour of 128 mm in dia-
meter), and Vcell is the volume of one cell. The follow-
ing linear form of this equation is obtained by solving
for b:
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Therefore, b can be determined by a linear regression
of the time and volume obtained from MRI data (as all
calculations in the present paper use a relative cancer
time, the choice of Vcell does not affect the given
estimates).
Actual tumour doubling time DTact was calculated for
each patient based on the first recorded tumour volume
V using the following equation:
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The primary endpoint was the tumour growth rate. Sec-
ondary endpoints were tumour volumes and tumour
sizes.
The primary objective of the present study was to
compare tumour growth rates between women without
personal history of breast cancer, with ipsilateral recur-
rence, and with contralateral recurrence. Secondary
objectives were to identify whether patient-, tumour- or
treatment-related parameters were linked to tumour
growth rates and to assess the reproducibility and accu-
racy of tumour volume measurements.
Statistical methods
The three female groups were compared for patient and
disease characteristics in order to verify group
= 17 women with previous
history of breast cancer
362 breast cancers diagnosed 
between 2005 and 2009 with
MRI at diagnosis
6 patients with regional non-
mass like enhancement
3 patients with no visible 
lesion on previous MRI exam
37 patients with at least 2 
MRI exams with visible and 
measurable tumor
316 patients had no prior 
breast MRI
46 patients had at least one 
breast MRI prior to diagnosis
7 women
with contralateral
recurrence
10 women
with ipsilateral
recurrence
20 women
with primary 
breast cancer
(i.e. no previous 
history of breast 
cancer)
Figure 1 Flow diagram.
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Page 3 of 9comparability and detect any confounding factor using
the Kruskal-Wallis one-way analysis of variance in case
of continuous variables and of the c2t e s to rF i s h e r ’s
exact test in case of categorical variables.
To test for differences in the distribution of tumour
growth rates across groups, menopausal status and his-
tological grades, we used the Kruskal-Wallis one-way
analysis of variance.
The Bonferroni correction was used to assess signifi-
cance in comparisons of growth rates among subgroups.
Tumour characteristics recorded as continuous vari-
ables (volume, hormone receptors, Ki67, mitotic count)
were dichotomized using the median as cut-off point.
Comparison of the distribution of tumour growth rates
between histological subtypes and dichotomized tumour
characteristics were performed by the Wilcoxon test.
Interobserver agreement in the volume measurements
and agreement between the major diameter measured
on MRI and at pathologic examination was assessed by
computing intraclass correlation coefficients.
P < .05 denoted statistical significance.
Computations were carried out using SAS version 9.2
software.
This study was not registered.
Role of the funding source
There was no funding source for this study.
Results
Participants
Table 1 details the patient characteristics.
All participants were over 40 years old (median age:
56 y., range: 40 - 72 years).
There was a higher rate of post-menopausal women in
the recurrence group and none of them had hormone
therapy (p = 0.02). Seven patients (36%) were pre-meno-
pausal and three women (15%) received hormone ther-
apy. Only 3 women were BRCA carriers, 2 with BRCA 1
mutation in the primary cancer group, and 1 with
BRCA 2 mutation with an ipsilateral recurrence.
Patients with no personal history of breast cancer and
patients with ipsi- or contralateral recurrences did not
differ in terms of age and mutation status (Table 1).
All recurrences were late recurrences, which were new
primary tumours, diagnosed at least 2 years after the
initial diagnosis of primary cancer, with a median time
interval of 10 years (range 2 - 19 years). All patients
with a personal history of breast cancer received radia-
tion therapy, except for one woman who underwent
mastectomy. Contralateral recurrences were diagnosed
earlier than ipsilateral recurrences (median: 8 years after
primary cancer vs 13 years, p = 0.003).
The median time interval between initial and final
MRI was 659 days (range, 134 - 1290 days).
Tumours
T h e r ew e r e3 2i n v a s i v ed u c t a lc a r c i n o m a s ,1i n v a s i v e
lobular carcinoma, and 4 ductal carcinomas in situ. The
median maximum tumour diameter at pathologic review
w a s1 0m m( r a n g e0-3 5m m ) .O n et u m o u rw a s
entirely removed at biopsy and no macroscopic cancer
was measurable at postsurgical pathology.
Initial and final tumour volumes on the first and last
MRI scans were, respectively, 139 mm
3 (8 - 4837) and
425 mm
3 (36 - 4373), with no significant difference
between the primary cancer and recurrence groups.
Recurrences and primary cancers did not differ in
terms of histological type, size, location, grade, hormone
receptors, Ki67 level, or mitotic count (Table 1).
Growth rate
Table 2 shows a comparison of growth rates in terms of
patient-, tumour- or treatment-related characteristics.
The overall growth rate of tumours was 2.18 10
-3
days
-1 (range: -1.41 - 5.79, actual doubling time: median
343 days, range -6797 - 4470). Two tumours demon-
strated a decrease in volume between the initial and
final MRI scans.
Analysis showed a significant accelerated growth rate
for contralateral recurrences compared to ipsilateral
recurrences or primary cancers (growth rate [10
-3 days
-1]:
3.56 vs 1.38 vs 2.09, respectively, p = 0.004) (Figure 2).
No significant differences in growth rate were found
between primary cancers and ipsilateral recurrences
(2.09 vs 1.38, p = NS).
When dichotomizing the tumours according to the
median initial volume (139 mm
3), the largest tumours
showed lower growth rates than the smallest tumours
(1.52 vs 2.73, p = 0.04), which is consistent with the
hypothesis of a decelerating tumour growth model.
The growth rate ranges of breast tumours of different
types and grades were wide and overlapped substan-
tially: growth rates did not differ in terms of other
patient characteristics (age, mutation status, menopausal
status), tumour characteristics (histological type, grade,
hormone receptors, Ki67 level, mitotic count), or pre-
vious cancer therapy.
Study of agreement
Inter-reader reliability for volume measurements and
agreement for maximum diameter measurement
between MRI and pathological examination assessed by
the intraclass correlation coefficient were respectively
0.96 (95% CI: 0.94 - 0.97) and 0.91 (95% CI: 0.83 - 0.95).
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Although preclinical studies suggest cancer treatments
can accelerate tumour growth, assessing tumour pro-
gression prospectively in patients without therapeutic
intervention is not feasible due to obvious ethical issues.
To date and to our knowledge, no observational study
has investigated the growth rate of late breast cancer
recurrences with MRI. Very few simulation studies and
retrospective clinical analyses have been published on
the growth rate of human breast cancers [16]. Moreover,
Table 1 Characteristics of patient groups
Primary
breast cancer
Recurrence
of breast
cancer
Ipsilateral
recurrence
Contralateral recurrence P
Characteristic (n = 20) (n = 17) (n = 7) (n = 10)
Age at detection (years)
Median (range) 56 (40-72) 60 (44-78) 57 (53-64) 62 (44-78) 0.61
Menopausal status
Pre- 6 (30%) 1 (6%) 1 (14%) 0 (0%)
Post-, with HT 3 (15%) 0 (0%) 0 (0%) 0 (0%) 0.11
Post-, without HT 11 (55%) 16 (94%) 6 (86%) 10 (100%)
Mutation
BRCA 1 2 (10%) 0 (0%) 0 (0%) 0 (0%) 0.24
BRCA 2 0 (0%) 1 (5.9%) 1 (14%) 0 (0%)
Delay between cancers
10 (2 - 19) 13 (9-19) 8 (2-17) .003
Histologic type of primary cancer
IDC/ILC 12 (75%) 6/7 (86%) 6/9 (67%)
DCIS 4 (25%) 1/7 (14%) 3/9 (33%)
Treatment of primary breast cancer
Surgery 0.48
Breast-conserving surgery 15 (88%) 7/7 (100%) 8/10 (80%)
Mastectomy 2 (12%) 0/7 (0%) 2/10 (20%)
Radiotherapy 16 (94%) 7/7 (100%) 9/10 (90%) 1
Chemotherapy 8 (47%) 2/7 (29%) 6/10 (60%) 0.33
Hormonal therapy 4 (27%) 1/6 (17%) 3/9 (33%) 0.60
Location of cancer
Inner 3 (15%) 5 (29%) 1 (14%) 4 (40%)
Central 4 (20%) 1 (6%) 1 (14%) 0 (0%) 0.43
Outer 13 (65%) 11 (65%) 5 (17%) 6 (60%)
Histology of new cancer 1.00
Invasive carcinoma 18 (90%) 15 (88%) 6 (86%) 9 (90%)
SBR 1 9 (50%) 4 (22%) 2 (33%) 2 (22%)
SBR 2 5 (28%) 9 (60%) 3 (50%) 6 (67%) 0.51
SBR 3 4 (22%) 2 (13%) 1 (7%) 1 (11%)
DCIS 2 (10%) 2 (12%) 1 (14%) 1 (10%)
Tumour size
Maximum tumour diameter at pathologic review (mm) 9
(0 - 28)
10
(2 - 35)
10
(2 - 18)
8.5
(5 - 35)
0.97
Initial volume (mm3) 244 (14 - 4837) 121 (8 - 2806) 121 (26 - 612) 116 (8 - 2806) 0.44
Final volume (mm3) 357 (36 - 4373) 425 (68 - 4319) 359 (100 - 1355) 458 (68 - 4319) 0.90
Hormone receptors
Oestrogen receptors 80 (0-100) 95 (20 - 100) 90 (60 - 100) 100 (20 - 100) 0.06
Progesterone receptors 30 (0 - 95) 40 (0 - 95) 25 (2 - 95) 55 (0 - 90) 0.99
Ki67
Median (range) 6 (1 - 35) 12 (2 - 40) 12 (5 - 30) 12.5 (2 - 40) 0.09
Mitotic count
Median (range) 2 (0 - 31) 7 (1 - 20) 3.5 (1 - 10) 9 (1 - 20) 0.20
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Page 5 of 9Table 2 Comparison of tumour growth rates
Characteristic n Growth rate
b (10
-3 days
-1)
Actual doubling time
DTact (days)
P
Age at detection
< 59 y. (median) 18 2.01 (-1.41 - 5.77) 341 (-685 - 785) 0.79
>= 59 y. 19 2.21 (-0.12 - 5.79) 343 (-6797 - 4470)
Menopausal status
Pre- 7 2.73 (1.25 - 3.98) 293 (193 - 651)
Post-, with hormone therapy 3 -0.12 (-1.41 - 2.18) -685 (-6797 - 343) 0.14
Post-, without HT 27 2.22 (0.18 - 5.79) 344 (129 - 4470)
Personal history
No previous breast cancer 20 2.09 (-1.41 - 3.98) 284 (-6797 - 4470)
Ipsilateral recurrence 7 1.38 (1.10 - 2.22) 581 (344 - 710) 0.004
Contralateral recurrence 10 3.56 (1.65 - 5.79) 221 (129 - 481)
Contralateral recurrence
No 27 1.69 (-1.41 - 3.98) 390 (-6797 - 4470) 0.001
Yes 10 3.56 (1.65 - 5.79) 221 (129 - 481)
Treatment of primary breast cancer
Surgery
Breast-conserving surgery 15 2.12 (1.10 - 5.77) 355 (129 - 710) 0.19
Mastectomy 2 4.02 (2.26 - 5.79) 237 (130 - 344)
Radiotherapy
No 1 5.79 (5.79 - 5.79) 130 (130 - 130) 0.10
Yes 16 2.17 (1.10 - 5.77) 349 (129 - 710)
Chemotherapy
No 9 2.02 (1.10 - 5.79) 390 (129 - 710) 0.71
Yes 8 2.24 (1.19 - 5.76) 344 (141 - 660)
Hormonal therapy
No 11 2.26 (1.10 - 5.79) 344 (129 - 710) 0.90
Yes 4 2.51 (1.19 - 5.76) 335 (141 - 660)
Location of cancer
Inner 8 2.09 (1.10 - 5.79) 376 (129 - 785)
Central 5 2.89 (1.38 - 3.33) 293 (245 - 604) 0.70
Outer 24 2.17 (-1.41 - 5.76) 330 (-6797 - 4470)
Histology
Invasive carcinoma 33 2.21 (-0.12 - 5.79) 343 (-6797 - 4470) 0.17
In situ carcinoma 4 0.75 (-1.41 - 5.76) 401 (-685 - 2643)
Grade
SBR 1 13 2.00 (0.18 - 3.82) 409 (192 - 4470)
SBR 2 14 2.59 (-0.12 - 5.79) 273 (-6797 - 710) 0.17
SBR 3 6 2.81 (1.10 - 3.35) 284 (234 - 785)
Tumour initial volume
< 139 mm3 (median) 18 2.73 (0.91 - 5.79) 274 (129 - 817) 0.04
≥ 139 mm3 19 1.52 (-1.41 - 5.76) 399 (-6797 - 4470)
Oestrogen receptors
< 90% (median) 15 2.22 (-0.12 - 5.77) 293 (-6797 - 4470) 0.75
≥ 90% 17 2.12 (0.91 - 5.79) 355 (130 - 817)
Progesterone receptors
< 35% (median) 16 1.95 (-0.12 - 3.84) 318 (-6797 - 785) 0.44
>= 35% 16 2.22 (0.18 - 5.79) 343 (129 - 4470)
Ki67
< 7.5% (median) 13 2.18 (-0.12 - 5.77) 265 (-6797 - 4470) 0.67
≥ 7.5% 13 2.26 (1.10 - 5.79) 344 (130 - 710)
Mitotic count
< 3.5 (median) 16 2.01 (0.18 - 3.98) 399 (192 - 4470) 0.17
≥ 3.5 16 2.81 (-0.12 - 5.79) 284 (-6797 - 785)
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has a lower sensitivity and ability to evaluate tumour
size as compared to MRI [12,13,15]. Growth rate esti-
mations from screening populations also have weak
points as chosen mathematical models of tumour
growth and screening test sensitivity are controversial
[13,15]. One author even tried to evaluate the tumour
growth rate with the lesion not always being visible in
the imaging examinations, while setting a default size
for non-visible tumours [16,17].
Since MRI allows for accurate measurement of
tumour volume, and as several MRI exams are some-
times needed to suggest malignancy, breast tumour
growth rates could be measured in a retrospective fash-
ion. It was therefore the first goal of the present study
to assess whether breast cancer recurrences have an
accelerated growth rate compared to primary cancers.
The median growth rate of the breast cancers in our
study (DTact: 343 days, range -6797 - 4470), which was
measured volumetrically using serial MRI, was lower than
previously reported measured or estimated growth rates
[12,15,17]. This difference might be explained by the wide
growth rate range and potential selection bias due to over-
looked MRI lesions being small cancers [12,15,16].
The main weaknesses of our study are a small sample
s i z ea n dam i x e dp o p u l a t i o n .C o n c l u s i o n sa r ed r a w n
from 37 patients with both ductal and lobular carcino-
mas. Despite the small sample size, univariate analysis
suggests that contralateral breast cancer recurrences
may show accelerated tumour growth compared to ipsi-
lateral recurrences and primary cancers, with statistical
significance. Unfortunately,m u l t i v a r i a t ea n a l y s i so fo u r
data is limited by the sample size.
Mathematical modelling of human breast cancer
growth is still controversial, and differences in growth
rates between the largest and smallest tumours in our
study suggest that the model fitting was not perfect.
Hence, in addition to the chosen model, we also evalu-
ated Gompertzian and exponential growth models,
which delivered the same results with regard to the pri-
mary endpoint.
Among the interesting questions arising from this
study is whether the growth of recurrences could be
promoted by contralateral cancer treatment.
First of all, there was no apparent difference in the
patient or tumour characteristics between patients with
contralateral recurrence vs ipsilateral recurrence or pri-
mary cancer, although the small sample size minimizes
the certainty of this observation.
Despite our hypothesis that recurrences would grow
faster, no significant differences were noted in the
growth rate of primary cancers and ipsilateral recur-
rences. This is consistent with the results of previous
studies that have provided solid evidence that radiation
therapy decreases the risk of locoregional recurrence,
and is associated with improved survival in high-risk
patients with breast cancer [18]. Moreover, women who
have received chemotherapy or hormonal therapy do
not seem to have higher tumour growth rates than
women who did not receive such therapies. Cancer
treatment at curative dose does not seem to accelerate
late recurrence growth in treated breasts [19].
Finally, radiation therapy is the only factor that differ-
entiates contralateral breasts from breasts treated for
primary cancer. Although previous studies suggested
that radiation therapy can promote accelerated repopu-
lation[20] and radiation-induced breast cancer, particu-
larly in young women, data regarding the radiation
therapy associated risk of contralateral breast cancer are
controversial [21-24].
A review of randomized trials reported an excess of
cancer incidence among women allocated radiotherapy
that mainly involved contralateral breast, during a 5-14
year period after randomisation, including among
women aged 50 years or older [18].
Several hypotheses can be put forward to explain the
potential harmful effects of radiation therapy on contral-
ateral breast cancer.
During external beam therapy of malignant breasts,
the contralateral breast receives radiation due to leakage
from collimator and scatter from primary. The dose to
the contralateral breast has been estimated to be around
5 Gy for 50 Gy primary breast dose [25-27].
Figure 2 Comparison of tumour growth rates between patients
with primary breast cancer, ipsilateral, or controlateral
recurrence of breast cancer.
Millet et al. BMC Cancer 2011, 11:155
http://www.biomedcentral.com/1471-2407/11/155
Page 7 of 9Ionizing radiation on contralateral breasts results in
DNA and stromal injuries that can accelerate tumour
growth [1,28].
Another possible explanation for increased cancer
growth may be systemic effects of local radiation ther-
apy mediated by immune or inflammatory systems such
as TNFa [29-31]. Indeed, long-term production of
TNFa at infraclinical levels is capable of promoting
carcinogenesis.
Conclusion
Despite its retrospective uncontrolled design and small
sample size, this study suggests that late contralateral
breast cancer recurrences may have accelerated growth.
This may be provoked by prior radiation therapy in the
primary treated breast. Consequently, newer radiation
therapy techniques should be investigated with regard to
their roles as risk factors for secondary breast cancer in
the contralateral breast.
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